Pregled bibliografske jedinice broj: 538812
Rapamycin enhances dimethyl sulfoxide-mediated growth arrest in human myelogenous leukemia cells
Rapamycin enhances dimethyl sulfoxide-mediated growth arrest in human myelogenous leukemia cells // Liječnički vjesnik
Zagreb, 2011. str. 87-87 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 538812 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Rapamycin enhances dimethyl sulfoxide-mediated growth arrest in human myelogenous leukemia cells
Autori
Lalić, Hrvoje ; Lukinović-Škudar, Vesna ; Banfić, Hrvoje ; Višnjić, Dora
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Liječnički vjesnik
/ - Zagreb, 2011, 87-87
Skup
Leukemia and Lymphoma East and West are together
Mjesto i datum
Dubrovnik, Hrvatska, 17.09.2011. - 21.09.2011
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
rapamycin; DMSO; leukemia
Sažetak
Aim: The pharmacological inhibitors of phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway have been proposed in the treatment of leukemia based on their antiproliferative effects, but their possible role in differentiation therapy is less explored. Rapamycin, an mTOR-inhibitor, has been recently reported to potentiate all-trans retinoic acid-mediated differentiation of HL-60 and NB4 cell lines along granulocytic pathway, and monocytic differentiation of U937 cells induced by vitamin D3. Dimethyl sulfoxide (DMSO) is a potent inducer of granulocytic differentiation of myeloid cell lines and erythroid differentiation of K562 cells. The aim of the present study was to test for the possible synergistic effects of rapamycin and DMSO on growth arrest and differentiaton of human myelogenous leukemia cells. Materials and Methods: Myeloblastic (AML-M2) HL-60, promyelocytic (AML-M3) NB4, monocytic (AML-M5) U937, immature (AML-M6) KG-1, and erythro-megakaryocytic K562 cell lines were maintained in exponential growth and differentiated in the presence of DMSO (0.6 or 1.25%). The number of viable cells was quantified using a hemocytometer and trypan blue exclusion. The expression of differentiation markers and the cell cycle distribution of propidium iodide-labeled cells were determined by FACS analyses. Cell morphology was evaluated on May-Grunwald-Giemsa-stained cytospin preparations. The level of phosphorylated (Thr389) and total p70 S6 Kinase (p70 S6K) in total cell lysates was determined by Western blot analysis. Results: Western blot analysis demonstrated that the incubation of leukemia cells in the presence of 20 nM rapamycin for 20 min completely reduced the level of Thr389-phosphorylated p70 S6K, which is one of the principle downstream targets of activated mTOR. When applied at the same dose for 96 h, rapamycin alone exerted minimal antiproliferative effects ; significant decrease in the number of viable cells was observed in rapamycin-treated HL-60 and KG-1 cells. The presence of 1.25% DMSO for 96 h significantly inhibited the growth of all cell lines tested, and the combination of rapamycin and DMSO inhibited the number of viable cells significantly more than either agent alone. FACS analysis of propidium iodide-labeled cells revealed a synergistic effect of rapamycin and DMSO on cell cycle arrest in G0/G1 phase. Conclusion: Rapamycin potentiates growth-inhibitory effects of DMSO in the established acute myeloid leukemia lines. These results suggest that mTOR inhibitors may have beneficial effects in combination with differentiation agents in therapy of AML.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081347-0173 - Funkcija fosfoinozitol 3-kinaze C2 beta u staničnim jezgrama (Banfić, Hrvoje, MZOS ) ( CroRIS)
108-1081347-1448 - Uloga PLC i Akt u staničnom ciklusu i diferencijaciji leukemija (Višnjić, Dora, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb